Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-10504 in Advanced NSCLC
NCT06461156Phase 1Recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Jun 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HS-10504 in non-small cell lung cancer (NSCLC), sponsored by Hansoh Pharmaceutical Group. Primary endpoint: Maximum Tolerated Dose at 21 days. Started Jun 2024; status: recruiting.
02
Drugs
HS-10504
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06461156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06461156.